SCHEMBL1622669

SCHEMBL1622669

N#Cc1c(N)c2ccccc2[nH]c1=O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE9A O76083 9/20 0.62
PDE1C Q14123 1/20 0.56
KDM4E B2RXH2 7/20 0.53
ALDH1A1 P00352 5/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
PARP1 P09874 3/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
HSD17B10 Q99714 2/20 0.48
LMNA P02545 2/20 0.48
TNKS O95271 1/20 0.48
CYP1A2 P05177 1/20 0.48
GPR3 P46089 1/20 0.48
BLM P54132 1/20 0.48
PMP22 Q01453 1/20 0.48
PARP15 Q460N3 1/20 0.48
TNKS2 Q9H2K2 1/20 0.48
HPGD P15428 2/20 0.48
FGFR1 P11362 2/20 0.47
FLT1 P17948 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1621734 0.79 PDE9A (0.62) PDE9APDE1CKDM4EALDH1A1SMN1; SMN2
SCHEMBL13913155 0.79 KDM5A (0.63) PDE9APDE1CKDM4EALDH1A1MEN1
SCHEMBL7915031 0.79 PDE9A (0.64) PDE9APDE1CKDM4EALDH1A1PARP1
SCHEMBL26127493 0.78 PARP1 (0.53) KDM4ESMN1; SMN2PARP1LMNACHEK1
SCHEMBL30608038 0.78 PARP1 (0.53) KDM4ESMN1; SMN2PARP1LMNACHEK1
SCHEMBL6343134 0.77 KDM4E (0.62) KDM4EALDH1A1SMN1; SMN2PARP1MEN1
SCHEMBL5618046 0.77 PDE9A (1.00) PDE9APDE1CKDM4EALDH1A1MEN1
SCHEMBL14607233 0.76 PDE9A (0.57) PDE9APDE1CKDM4EALDH1A1PARP1
SCHEMBL9034264 0.74 ALDH1A1 (0.44) PDE9AKDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL5858501 0.74 PLA2G1B (0.59) PDE9APDE1CKDM4EALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024107445-A1 ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES FREEDOM BIOSCIENCES, INC. (US) 2024-05-23 WO disclosed
US-20240065302-A1 SWEETENER COMPOSITIONS COMPRISING MOGROSIDES AND USES THEREOF FIRMENICH INCORPORATED 2024-02-29 US disclosed
CN-107365319-B Modulation of chemosensory receptors and ligands associated therewith 弗门尼舍公司 2020-10-27 CN disclosed
US-10376504-B2 Substituted quinolinones as PDE9 inhibitors Merck, Sharp & Dohme Corp. (US) 2019-08-13 US disclosed
EP-2573559-B1 Modulation of chemosensory receptors and ligands associated therewith SENOMYX INC (US) 2019-03-13 EP disclosed
US-20180214439-A1 AZA-CYANOQUINOLINONE PDE9 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2018-08-02 US disclosed
US-20180086751-A1 SWEETENER COMPOSITION SENOMYX, INC. 2018-03-29 US disclosed
WO-2017019723-A1 AZA-CYANOQUINOLINONE PDE9 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2017-02-02 WO disclosed
EP-2062050-B1 MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH SENOMYX INC (US) 2016-05-18 EP disclosed
EP-2062050-B1 MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH SENOMYX INC (US) 2016-05-18 EP disclosed
US-20110224155-A1 MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH SENOMYX INC. (US) 2011-09-15 US disclosed
US-20110224155-A1 MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH SENOMYX INC. (US) 2011-09-15 US disclosed
US-7928111-B2 Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors SENOMYX, INC. (US) 2011-04-19 US disclosed
US-7928111-B2 Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors SENOMYX, INC. (US) 2011-04-19 US disclosed
CN-101779124-A modulation of chemosensory receptors and ligands associated therewith SENOMYX INC 2010-07-14 CN disclosed
EP-2062050-A2 MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH Senomyx, Inc. (US) 2009-05-27 EP disclosed
WO-2008154221-A2 MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH SENOMYX, INC. (US) 2008-12-18 WO disclosed
WO-2008154221-A2 MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH SENOMYX, INC. (US) 2008-12-18 WO disclosed
US-20080306053-A1 MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH SENOMYX, INC. (US) 2008-12-11 US disclosed
US-20080306053-A1 MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH SENOMYX, INC. (US) 2008-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180086751-A1 SWEETENER COMPOSITION TAS2R50, TAS1R2, TAS2R10 PDE9A 2637/4885PDE1C 4224/4885KDM4E 2019/4885
US-20080306053-A1 MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH OR51E2, TAS2R50, TAS2R30 PDE9A 1124/4885PDE1C 737/4885KDM4E 4397/4885
US-10376504-B2 Substituted quinolinones as PDE9 inhibitors PDE9A, PDE5A, PDE2A PDE9A 1/4885PDE1C 26/4885KDM4E 1135/4885
US-20180214439-A1 AZA-CYANOQUINOLINONE PDE9 INHIBITORS PDE9A, PDE7B, PDE5A PDE9A 1/4885PDE1C 24/4885KDM4E 1117/4885
US-20110224155-A1 MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH TAS2R30, TAS2R50, TAS2R1 PDE9A 1815/4885PDE1C 834/4885KDM4E 4555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.